A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer
Crossref DOI link: https://doi.org/10.1007/s00404-017-4293-0
Published Online: 2017-02-03
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lavie, Ofer
Edelman, David
Levy, Tally
Fishman, Ami
Hubert, Ayala
Segev, Yakir
Raveh, Eli
Gilon, Michal
Hochberg, Avraham
License valid from 2017-02-03